ERIS Lifesciences Ltd share price logo

ERIS Lifesciences Ltd Share Price (ERIS)


Get free price alerts. Set up your Free investment account to get Live Prices. >
Q3 '23 Results
News and Events

Overview of ERIS Lifesciences Ltd

Key events for ERIS Lifesciences Ltd

  • Prabhudas Lilladher Rates Eris Lifesciences as BUY - 09 Apr, 2024

    Prabhudas Lilladher has given a BUY rating to Eris Lifesciences with a target of Rs 1,100. The company is expected to benefit from patent expirations in the cardiometabolic market and operating leverage as revenue scales up from acquisitions.

  • ERIS Lifesciences to Acquire Biocon Biologics' India Branded Formulation Business - 18 Mar, 2024

    ERIS Lifesciences has agreed to acquire the India branded formulation business of Biocon Biologics for INR12.4b, expanding its presence in the domestic injectable market in diabetes and oncology areas. The deal is valued at 12x 1-year forward EV/EBITDA, implying 25% YoY growth in EBITDA after the acquisition. ERIS also proposed to buy a 19% stake in Swiss Parenterals from ERIS promoters for INR2.4b.

  • Eris Lifesciences Enters Indian Injectables Market with Acquisition of Biocon Business - 15 Mar, 2024

    Eris Lifesciences is set to enter the Indian injectables market with the acquisition of Biocon Biologics India's branded formulation business for Rs 1,242 crore. The deal brings two major insulin brands under Eris and marks its entry into oncology and critical care.

  • Eris Lifesciences Acquires Biocon's Branded Formulations Business - 14 Mar, 2024

    Eris Lifesciences has acquired Biocon Biologics' Branded Formulations business in India for Rs 1,242 crore, giving it a leadership position in the insulin division and putting it in the oncology and critical care industries. The acquisition brings two leading insulin products under Eris's umbrella, propelling its diabetes care unit to potentially earn Rs 1,000 crore in revenue.

  • HDFC Securities Recommends Buy on Eris Lifesciences with Target Price of Rs 1070 - 13 Mar, 2024

    Eris Lifesciences Ltd. is a mid-cap pharmaceutical company with a market cap of Rs 11,707.95 crore. HDFC Securities has recommended a buy call on the stock with a target price of Rs 1070, citing strong financials and growth prospects.

Analyst Rating for ERIS Lifesciences Ltd stock

based on 8 analysts


Based on 8 analysts offering long term price targets for ERIS Lifesciences Ltd. An average target of ₹1080.62

Source: S&P Global Market Intelligence

ERIS Lifesciences Ltd share Performance

  • ₹839.65
    downward going graph



    Day's Volatility:1.49%



    downward going graph
  • ₹581
    downward going graph



    52 Weeks Volatility:46.13%



    downward going graph
1 Month Return1.93 %
3 Month Return-7.85 %
1 Year Return41.92 %
Previous Close₹846.00
Upper Circuit-
Lower Circuit-
Market Cap₹11,509.62Cr

ERIS Lifesciences Ltd Company Information

Eris Lifesciences Limited was incorporated in 2007 and is engaged in manufacturing, distributing and marketing of branded pharmaceutical products, having presence in high growth chronic, sub-chronic and acute therapeutic areas. It has a portfolio of 112 Mother Brands across therapy areas and 5 subsidiaries, 4 of which are wholly owned subsidiaries. The company has made two acquisitions - UTH Healthcare Ltd for Rs 129 million for its product portfolio in 2017 and Indian branded formulations business Strides for Rs 5000 crore in 2017. It made its debut in secondary equity market in 2017 and in FY 2018 capital expenditure amounted to Rs 242.69 million and Rs 5061.52 million was paid towards business acquisition. In FY 2019 the company expanded its operations by constructing new softgel facility, extended facility for supplements and nutraceuticals, and added Zomelis products in its portfolio. In 2020, Kinedex became wholly owned subsidiary and the company launched new business divisions. In FY21 it launched Gluxit in SGLT2 segment, Eritel and LNBloc maintained ranks in their respective segments, developed Bricet and fortified portfolio with the launch of ZACD. In FY22 it acquired 100 stake in Oaknet Healthcare Ltd worth Rs 6500 million and launched human insulin through its subsidiary Eris M.J. Biopharm Ltd and Xsulin in vials and cartridges.

Share Price: ₹847.35 per share as on 12 Apr, 2024 04:01 PM
Market Capitalisation: ₹11,509.62Cr as of today
Revenue: ₹483.48Cr as on December 2023 (Q4 23)
Net Profit: ₹101.46Cr as on December 2023 (Q4 23)
Listing date: 29 Jun, 2017
Chairperson Name: Amit Indubhushan Bakshi
OrganisationERIS Lifesciences Ltd
E-voting on sharesClick here to vote

Fundamentals of ERIS Lifesciences Ltd

Insights on ERIS Lifesciences Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.


    Retail Holding Up


    Retail Investor have increased holdings from 17.37% to 17.41% in Dec 2023 quarter


    Price Rise


    In the last 1 month, ERIS stock has moved up by 1.9%

  • imgNO EFFECT

    Against Peers


    In the last 1 year, Zydus Lifesciences Ltd has given 91.0% return, outperforming this stock by 49.1%

  • imgNO EFFECT

    Against Peers


    In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 145.5% return, outperforming this stock by 102.5%


    FII Holding Down


    Foreign Institutions have decreased holdings from 13.20% to 13.14% in Dec 2023 quarter


    Promoter Holding Down


    Promoters have decreased holdings from 54.91% to 54.90% in Dec 2023 quarter


    Revenue Fall


    Revenue is down for the last 2 quarters, 508.78 Cr → 490.49 Cr (in ₹), with an average decrease of 3.6% per quarter


    MF Holding Down


    Mutual Funds have decreased holdings from 13.86% to 13.85% in Dec 2023 quarter


    Profit Down


    Netprofit is down for the last 2 quarters, 123.43 Cr → 102.74 Cr (in ₹), with an average decrease of 16.8% per quarter

ERIS Lifesciences Ltd Valuation

ERIS Lifesciences Ltd in the last 5 years

  • Overview

  • Trends

Lowest (16.77x)

September 9, 2019

Today (29.83x)

April 12, 2024

Industry (62.56x)

April 12, 2024

Highest (39.79x)

March 13, 2018


ERIS Lifesciences Ltd Mutual Fund Holdings

Funds Holdings
HDFC Small Cap Fund-Direct Growth OptionHDFC Small Cap Fund-Direct Growth Option1.69%
UTI Flexi Cap Fund - Growth Option - DirectUTI Flexi Cap Fund - Growth Option - Direct0.78%
HDFC Hybrid Equity Fund Direct Growth OptionHDFC Hybrid Equity Fund Direct Growth Option0.69%
Franklin India Smaller Companies Fund Direct GrowthFranklin India Smaller Companies Fund Direct Growth1.25%
UTI Value fund Fund-Direct Growth OptionUTI Value fund Fund-Direct Growth Option1.01%

ERIS Lifesciences Ltd Shareholding Pattern

InvestorsHoldings %Prev. 4 periods3M change
Promoter Holdings
Foreign Institutions
Mutual Funds
Retail Investors

Technicals of ERIS Lifesciences Ltd share

News & Events of ERIS Lifesciences Ltd

Frequently Asked Questions

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy ERIS Lifesciences Ltd shares.

ERIS Lifesciences Ltd (ERIS) share price today is ₹847.35

ERIS Lifesciences Ltd is listed on NSE

ERIS Lifesciences Ltd is listed on BSE

  • Today’s highest price of ERIS Lifesciences Ltd is ₹852.25.
  • Today’s lowest price of ERIS Lifesciences Ltd is ₹839.65.

PE Ratio of ERIS Lifesciences Ltd is 29.83

PE ratio = ERIS Lifesciences Ltd Market price per share / ERIS Lifesciences Ltd Earnings per share

Today’s traded volume of ERIS Lifesciences Ltd(ERIS) is 46.13K.

Today’s market capitalisation of ERIS Lifesciences Ltd(ERIS) is ₹11509.62Cr.

ERIS Lifesciences Ltd(ERISPrice
52 Week High
52 Week Low

ERIS Lifesciences Ltd(ERIS) share price is ₹847.35. It is down -12.82% from its 52 Week High price of ₹971.9

ERIS Lifesciences Ltd(ERIS) share price is ₹847.35. It is up 45.84% from its 52 Week Low price of ₹581

ERIS Lifesciences Ltd(ERISReturns
1 Day Returns
1 Month Returns
3 Month Returns
1 Year Returns